Each advisor brings essential knowledge and experience, providing immediate impact to Proscia and signaling our commitment to building the future of digital pathology including disease-specific AI applications for precision medicine.
BALTIMORE (PRWEB) October 17, 2017
Proscia Inc., a data solutions provider for digital pathology, announces today the formation of its Board of Advisors (BOA), further strengthening the company and solidifying its mission to drive the adoption of computational pathology. Proscia’s newly formed BOA includes scientists with deep knowledge of anatomic and computational pathology, precision medicine, and diagnostics. The board will guide Proscia in shaping strategy and defining the next generation of digital pathology solutions including its pipeline of AI-based, cancer-specific algorithms.
The BOA is comprised of the following individuals:
Alexander Spyridon Baras, MD, PhD. Dr. Baras heads Precision Medicine Informatics and Bioinformatics for the Sidney Kimmel Comprehensive Cancer Center and the Molecular Diagnostics Laboratory at Johns Hopkins, which leverages clinical genomics data of malignancies. Effectively coupling a robust characterization of tissue specimens to these new technologies will optimally inform their use in the development of novel clinical diagnostics and therapeutic regimens. As a pathologist and bioinformatician in this field, Dr. Baras is advancing the front line of translational biomedical research, combining clinical, computational, and molecular techniques centered on tissue specimens with the ultimate goal of improving patient care.
Dr. Baras also oversees the Oncology Tissue Services laboratory and the digital pathology slide scanning serving of the Oncology Tissue Services laboratory, along with the Department of Pathology.
Dr. Baras is a practicing pathologist specializing in genitourinary pathology with a comprehensive understanding of cellular and molecular research along with bioinformatics. He completed a residency in anatomic pathology at the Johns Hopkins University and an MD and PhD from the University of Virginia.
Dr. Baras believes the implementation of high-throughput, global analytic methodologies for various biomolecules is ushering in a new era of discovery in disease pathogenesis. Leveraging these technologies in the development of novel diagnostics and therapeutic approaches is a critical aspect of precision medicine. With these new technologies, which can be based on tissue morphology, protein expression, RNA analysis, genomic analysis, or other cellular features, scientists are uniquely poised to detect previously unidentified features of disease that can better guide patient management and treatment.
Anthony M. Magliocco, MD, FRCPC, FCAP. Dr. Magliocco is a Board Certified molecular and anatomical pathologist. He is currently Chair of Anatomic Pathology and Executive Director of Esoteric Laboratory Services at the Moffitt Cancer Center. He also serves as the Scientific Director of the Moffitt Tissue Core.
In these roles, Dr. Magliocco has overseen the implementation of next generation sequencing, liquid biopsy, nanostring, and advanced quantitative digital imaging microscopy technology into routine care at the Moffitt Cancer Center. He is also co-chair of pathology for the NRG cooperative clinical trials group and was recently appointed to the NIH NCI Genitourinary Steering Committee.
Dr. Magliocco completed a fellowship at the Fox Chase Cancer Center in Philadelphia, Pennsylvania, and residency at the University of Calgary. He earned his medical degree at the University of Alberta in Edmonton, Alberta, Canada. Dr. Magliocco has subspecialty expertise in women's cancers (breast, gynecologic) and conducts scientific research into the molecular basis of metastasis and the development and implementation of novel diagnostic assays into routine CLIA testing.
Dr. Magliocco has authored over 170 manuscripts and awarded multiple patents. He also operates a basic science laboratory with a focus on the identification of novel biomarkers for the improved diagnosis and management of women’s cancers.
Michael H. A. Roehrl, MD, PhD., FCAP. Dr. Roehrl is Board-certified in both anatomic and clinical pathology. He is founding Director of the Precision Pathology Center, Principal Investigator, and Associate Attending Physician at Memorial Sloan Kettering Cancer Center in New York City. He is also a Member of the Human Oncology and Pathogenesis Program at MSKCC.
He has extensive expertise in gastrointestinal cancers and molecular diagnostics. Dr. Roehrl completed his residency at Massachusetts General Hospital in Boston, MA, and earned his medical degree from TUM Medical School in Munich, Germany, and his PhD in Biological Chemistry from Harvard University. Prior to moving to New York City, Dr. Roehrl held academic faculty appointments in Boston and at the University of Toronto and the Ontario Institute for Cancer Research (OICR).
Dr. Roehrl’s research group works on novel biomarker discovery in solid tumors using a variety of biochemical, biophysical, and computational approaches, including digital imaging, mass spectrometry, integrated proteogenomics, and machine learning. Dr. Roehrl has been teaching national and international courses for USCAP, CAP, ASCP, ISBER, and other academic organizations.
Andries Zijlstra, PhD. Dr. Zijlstra is Associate Professor of Pathology, Microbiology and Immunology at Vanderbilt University. He has broad experience in oncology with a focus on the contribution of tumor cell motility to metastasis. Dr. Zijlstra uses collaborative efforts with industry and research institutions to develop biomarker strategies that improve the detection of aggressive cancers, predict disease-disease specific survival and response to therapy. In this effort he leverages both tissue-based biomarkers and soluble, circulating biomarkers. He is also actively engaged with the metastasis research community, serves on the board of the Metastasis Research Society and acts as consultant to industry partners with projects on molecular profiling of cancer.
"Each advisor brings essential knowledge and experience, providing immediate impact to Proscia and signaling our commitment to building the future of digital pathology including disease-specific AI applications for precision medicine," says David West, chief executive officer of Proscia. "The field of pathology has relied on human analysis of tissue using the simple light microscope for over 150 years. We feel it is time for pathology to embrace modern computing resources. Proscia -- alongside our talented team of scientists, engineers, scientific advisors, and board directors -- is transforming pathology to improve patient outcomes and accelerate breakthrough cancer research through machine learning and the next generation of precision medicine and analytic tools.”
Register now for Proscia’s webinar, “Pathology is going digital. Is your lab ready?”, taking place on October 19th at 4:00 p.m. EDT. Learn adopting digital pathology best practices and see how Proscia’s new computational pathology platform is transforming labs today.
Proscia was founded in 2014 by a team out of Johns Hopkins, the Moffitt Cancer Center, and the University of Pittsburgh to improve clinical outcomes and accelerate the discovery of breakthrough advancements in the fight against cancer. Using modern computing technologies that unlock hidden data not visible to the human eye and turning that data into valuable insights in the fight against cancer, the company is dedicated to improving the efficiency, speed and quality of pathology diagnostics and research. To learn more, please visit http://www.proscia.com.